CY1113157T1 - ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE - Google Patents

ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE

Info

Publication number
CY1113157T1
CY1113157T1 CY20121100893T CY121100893T CY1113157T1 CY 1113157 T1 CY1113157 T1 CY 1113157T1 CY 20121100893 T CY20121100893 T CY 20121100893T CY 121100893 T CY121100893 T CY 121100893T CY 1113157 T1 CY1113157 T1 CY 1113157T1
Authority
CY
Cyprus
Prior art keywords
antibiotic
factors
compositions
gram
activity against
Prior art date
Application number
CY20121100893T
Other languages
Greek (el)
Inventor
Ameriga Lazzarini
Luciano Gastaldo
Gianpaolo Candiani
Ismaela Ciciliato
Daniele Losi
Flavia Marinelli
Enrico Selva
Franco Parenti
Original Assignee
Sentinella Pharmaceuticals, Inc. ("Sentinella")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/035,296 external-priority patent/US7319088B2/en
Priority claimed from EP05723117A external-priority patent/EP1855705B1/en
Application filed by Sentinella Pharmaceuticals, Inc. ("Sentinella") filed Critical Sentinella Pharmaceuticals, Inc. ("Sentinella")
Publication of CY1113157T1 publication Critical patent/CY1113157T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε μια αντιβιοτική ουσία μικροβιακής προέλευσης, αυθαίρετα ονομασμένη αντιβιοτικό 107891 που παράγεται από τη ζύμωση του Microbispora sp. ATCC ΡΤΑ-5024, τα φαρμακευτικώς αποδεκτά άλατα και τις συνθέσεις τους και στη χρήση τους ως ένα αντιβακτηριακό παράγοντα που έχει ανασταλτική δραστικότητα ενάντια στα ευαίσθητα μικρόβια. Το αντιβιοτικό 107891 που είναι ένα σύνθετο που περιλαμβάνει δύο Παράγοντες, που ονομάζονται Παράγοντες Α1 και Α2, έχει δομή πεπτιδίου που περιέχει λανθειονίνη και μεθυλολανθειονίνη ως συστατικά που είναι τυπικά χαρακτηριστικά των αντιβιοτικών της ομάδας των λαντιβιοτικών. Το αντιβιοτικό 107891 και οι Παράγοντες του Α1 και Α2 παρουσιάζουν καλή αντιβακτηριακή δραστικότητα ενάντια στα γκραμ θετικά βακτηρίδια συμπεριλαμβανομένων των ανθεκτικών σε μεθικιλλίνη και ανθεκτικών σε βανκομυκίνη στελεχών και είναι δραστικοί επίσης ενάντια σε μερικά γκραμ αρνητικά βακτηρίδια όπως τα είδη Μ. catharralis και Neisseria και Η. influenzae και τα μυκοβακτήρια.The invention relates to an antibiotic substance of microbial origin, an arbitrarily named antibiotic 107891 produced by the fermentation of Microbispora sp. ATCC PTA-5024, their pharmaceutically acceptable salts and compositions and their use as an antibacterial agent having inhibitory activity against susceptible microbes. Antibiotic 107891 which is a compound comprising two Factors, called Factors A1 and A2, has a peptide structure containing lanthionionine and methylolanthionine as components typical of the antibiotics of the lantibiotic group. Antibiotic 107891 and Factors A1 and A2 exhibit good antibacterial activity against gram-positive bacteria including methicillin-resistant and vancomycin-resistant strains and are also active against some Gram-negative and Neisseria spp. influenzae and mycobacteria.

CY20121100893T 2005-01-12 2012-09-28 ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE CY1113157T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/035,296 US7319088B2 (en) 2003-07-18 2005-01-12 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
EP05723117A EP1855705B1 (en) 2005-01-12 2005-01-19 Antibiotic 107891, its factors, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
CY1113157T1 true CY1113157T1 (en) 2016-04-13

Family

ID=38346011

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100893T CY1113157T1 (en) 2005-01-12 2012-09-28 ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE

Country Status (6)

Country Link
KR (1) KR100892655B1 (en)
CY (1) CY1113157T1 (en)
MA (1) MA29144B1 (en)
PT (1) PT1855705E (en)
UA (1) UA87546C2 (en)
ZA (1) ZA200705494B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351687B2 (en) * 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218362B1 (en) * 1997-09-08 2001-04-17 Universite Laval Lantibiotic from Streptococcus mutans and uses thereof

Also Published As

Publication number Publication date
PT1855705E (en) 2012-10-16
MA29144B1 (en) 2008-01-02
ZA200705494B (en) 2008-11-26
KR100892655B1 (en) 2009-04-15
UA87546C2 (en) 2009-07-27
KR20070098903A (en) 2007-10-05

Similar Documents

Publication Publication Date Title
CY1113030T1 (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE
RU95101039A (en) Antibiotic derivatives of glycopeptides, method of synthesis, pharmaceutical composition
JP2009501718A5 (en)
WO2005070945A8 (en) Novel aminoglycoside antibiotic effective against methicillin resistant staphylococcus aureus (mrsa)
RU2011130278A (en) NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF GRAM-POSITIVE INFECTIONS
EA201070504A1 (en) CARBACEFEM β-LACTAM ANTIBIOTICS
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
DK1334117T3 (en) Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associated elements
JP2012513467A5 (en)
AR073917A1 (en) ANTIBIOTIC SYNERGISM
WO2010036000A3 (en) Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof
CY1113157T1 (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICAL SALTS AND COMPOSITIONS AND THEIR USE
WO2004098500A3 (en) CARBACEPHEM ss-LACTAM ANTIBIOTICS
NO20080314L (en) Bicyclic 6-alkylidene-penem B-lactamase inhibitors and B-lactam antibiotic combination: a broad spectrum of antibiotics
EA200701267A1 (en) ANTIBIOTIC 107891, ITS A1 AND A2 FACTORS, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS AND THEIR APPLICATION
Oli et al. Actinomycetes in Medical and Pharmaceutical Industries
ATE295852T1 (en) ANTIBIOTIC TRIPROPEPTINS AND METHOD OF THEIR PRODUCTION
Yoshida et al. Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus (MRSA)
Mar Soe et al. Ethyl gallate as a combination drug can overcome resistance in MRSA
Paukner et al. Extended spectrum pleuromutilins: potent translation inhibitors with broad-spectrum antibacterial activity in vitro and in vivo
Sader et al. In vitro activity and potency of the novel oxazolidinone MRX-I tested against contemporary clinical isolates of Gram-positive bacteria
Prasetyoputri et al. Antibiotic potentiators to combat resistance in methicillin-resistant Staphylococcus aureus (MRSA): A mini review
WO2010012381A8 (en) Streptospirole derivatives
Sader et al. Update on Daptomycin Activity and Spectrum When Tested Against Gram-Positive Strains Collected in European Medical Centers (2006)
DE60115851D1 (en) ANTI-INFECTANTS WHICH ARE USEFUL AGAINST MULTIPLE DRUGS RESISTANT BACTERIAL STRAINS